SCHEMBL2238065

SCHEMBL2238065

Cc1cc(CC(C)C)ccc1CC(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 3/20 0.47
RXRB P28702 3/20 0.47
GABRA1 P14867 1/20 0.46
GABRB2 P47870 1/20 0.46
RXRG P48443 1/20 0.46
PTGS1 P23219 4/20 0.45
PTGS2 P35354 4/20 0.45
LMNA P02545 2/20 0.45
CYP2C9 P11712 2/20 0.45
AKR1C3 P42330 2/20 0.45
CXCR1 P25024 2/20 0.45
CXCR2 P25025 2/20 0.45
ALB P02768 1/20 0.45
ESR1 P03372 1/20 0.45
ALOX5 P09917 1/20 0.45
RARB P10826 1/20 0.45
ADRB3 P13945 1/20 0.45
NFKB1 P19838 1/20 0.45
HTR2A P28223 1/20 0.45
NR1I3 Q14994 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29394461 1.00 RXRA (0.47) RXRARXRBGABRA1GABRB2RXRG
SCHEMBL27864666 0.85 GABRA1 (0.45) GABRA1GABRB2PTGS1PTGS2LMNA
SCHEMBL2237603 0.85 EPHX1 (0.46) GABRA1GABRB2PTGS1PTGS2LMNA
SCHEMBL11725833 0.85 GABRA1 (0.56) GABRA1GABRB2PTGS1PTGS2LMNA
SCHEMBL2283410 0.84 RXRA (0.53) RXRARXRBRXRGPTGS1LMNA
SCHEMBL11209139 0.81 RXRA (0.50) RXRARXRBRXRGPTGS2LMNA
SCHEMBL11719645 0.80 GAA (0.53) NFKB1TSHRNR1H4NPSR1
SCHEMBL23241569 0.79 RXRA (0.49) RXRARXRBRXRGPTGS1LMNA
SCHEMBL11305549 0.79 RXRA (0.49) RXRARXRBRXRGPTGS1LMNA
SCHEMBL2237046 0.78 CXCR1 (0.50) GABRA1GABRB2LMNACXCR1CXCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1590314-B1 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPÉ FARMACEUTICI S P A (IT) 2015-08-05 EP claimed
CN-104474314-A Composition for treating colds and preparation method of composition XI AN EFANGGONG PHARMACEUTICAL CO LTD 2015-04-01 CN claimed
US-8871784-B2 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them DOMPE'S.P.A. (IT) 2014-10-28 US claimed
US-20100267726-A1 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE PHA.R.MA S.P.A. (IT) 2010-10-21 US claimed
US-20060223842-A1 such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia DOMPÉ FARMACEUTICI S.P.A. (IT) 2006-10-05 US claimed
EP-1590314-A2 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dompe' S.P.A. (IT) 2005-11-02 EP claimed
WO-2004069782-A2 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE' S.P.A. (IT) 2004-08-19 WO claimed
EP-0700288-A1 INHIBITION OF HAIR GROWTH HANDELMAN, Joseph H. (US) 1996-03-13 EP claimed
WO-1994027586-A1 INHIBITION OF HAIR GROWTH HANDELMAN, JOSEPH, H. (US) 1994-12-08 WO claimed
CN-118239858-A Ibuprofen derivative and preparation method and application thereof 华南农业大学 2024-06-25 CN disclosed
US-20240076261-A1 METHOD FOR PREPARING HIGH-BULK-DENSITY IBUPROFEN SPHERICAL CRYSTAL AND PRODUCT THEREOF ZHEJIANG NHU COMPANY LTD. (CN) 2024-03-07 US disclosed
CN-117092236-A Method for efficiently determining concentration of ibuprofen in blood plasma 安领生物医药(苏州)有限公司 2023-11-21 CN disclosed
CN-116869973-A Ibuprofen gel patch and preparation method thereof 山东新华制药股份有限公司 2023-10-13 CN disclosed
CN-115838338-A Method for preparing amide 浙江工业大学 2023-03-24 CN disclosed
WO-1998034115-A1 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 1998-08-06 WO disclosed
WO-1998007671-A1 SEPARATING ENANTIOMERS BY MOLECULAR IMPRINTING IGEN, INC. (US) 1998-02-26 WO disclosed
US-5502081-A COMPOSITIONS FOR SURGICAL AIDS FORMED FROM REACTION OF CARBODIIMIDE WITH HYALURONIC ACID RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 1996-03-26 US disclosed
US-5356883-A Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use RESEARCH FOUNDATION OF STATE UNIVERSITY OF N.Y. (US) 1994-10-18 US disclosed
WO-1994002517-A1 WATER-INSOLUBLE DERIVATIVES OF HYALURONIC ACID AND THEIR METHODS OF PREPARATION AND USE ANIKA RESEARCH, INC. (US) 1994-02-03 WO disclosed
WO-1988003021-A2 TREATMENT OF GINGIVITIS WITH IBUPROFEN OR FLURBIPROFEN THE UPJOHN COMPANY (US) 1988-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267726-A1 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM CXCR2, MMP8, CXCR1 RXRA 29/4885RXRB 46/4885GABRA1 346/4885
US-20060223842-A1 such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia CXCR2, CXCR1, MMP8 RXRA 56/4885RXRB 120/4885GABRA1 1367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.